Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 20, 2026

Analog Devices Inc (ADI) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic ...

View original at finance.yahoo.com
“Cash and Short-term Investments: $3.4 billion.”
Verbatim excerpt from the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Communications revenue represented 15% of total revenue, up 22% sequentially and 79% year over year.

    60% confidence
  • Third-quarter 2026 revenue is expected to be $3.9 billion, plus or minus $100 million.

    60% confidence
  • Automotive revenue represented 24% of total revenue, up 8% sequentially and 2% year over year.

    60% confidence
  • The acquisition of Empower Semiconductor is not expected to contribute materially to revenue in the near term.

    60% confidence
  • Inventory increased by $81 million sequentially, with days of inventory at 168.

    60% confidence
  • There are concerns about potential choke points in the semiconductor supply chain, particularly in memory, which could affect consumer customers.

    60% confidence
  • There is a potential risk of increased competition in pricing as some competitors may use the inflationary environment to take shares.

    60% confidence
  • Operating margin reached 49%, up 350 basis points sequentially and 780 basis points year over year.

    60% confidence
  • Cash and short-term investments totaled $3.4 billion as of Q2 2026.

    60% confidence
  • Third-quarter 2026 operating margin is expected to be 49%, plus or minus 100 basis points.

    60% confidence
  • Third-quarter 2026 EPS is expected to be $3.30, plus or minus $0.15.

    60% confidence
  • A 50 basis point decline in gross margin is anticipated for the third quarter due to the absence of a one-time benefit from repricing the channel.

    60% confidence
  • ADI is seeing strong demand in AI-driven infrastructure investments, particularly in data center and ATE businesses.

    60% confidence
  • Industrial revenue represented 50% of total revenue, up 20% sequentially and 56% year over year.

    60% confidence
  • Revenue for Q2 2026 was $3.62 billion, up 15% sequentially and 37% year over year, representing a record quarter and exceeding the high end of guidance.

    60% confidence
  • Consumer revenue is expected to decline single digits sequentially in the third quarter due to inflationary pressures and consumer sentiment.

    60% confidence
  • Consumer revenue represented 11% of total revenue, flat sequentially and up 23% year over year.

    60% confidence
  • Gross margin improved to 73%, up 180 basis points sequentially and 360 basis points year over year, driven by favorable mix, higher utilization, and pricing.

    60% confidence
  • Free cash flow over the trailing 12 months was $4.6 billion, representing 36% of revenue.

    60% confidence
  • EPS for Q2 2026 was $3.09, up 26% sequentially and 67% year over year.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com